American Society of Hematology Annual Meeting

American Society of Hematology Annual Meeting - Oncology Nurse Advisor https://www.oncologynurseadvisor.com/conferences/american-society-of-hematology-annual-meeting/ Wed, 03 Jan 2024 19:27:36 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.3 https://www.oncologynurseadvisor.com/wp-content/uploads/sites/13/2024/01/cropped-CTA-ONA-HEM-favicon-32x32.png American Society of Hematology Annual Meeting - Oncology Nurse Advisor https://www.oncologynurseadvisor.com/conferences/american-society-of-hematology-annual-meeting/ 32 32 Venetoclax and Ibrutinib: A New Standard for Relapsed/Refractory MCL? https://www.oncologynurseadvisor.com/reports/venetoclax-ibrutinib-mcl-new-standard/ Wed, 27 Dec 2023 15:20:00 +0000 https://www.oncologynurseadvisor.com/?p=114940 Older man holding glass of water looking at pill in kitchen

Older man holding glass of water looking at pill in kitchen

Adding venetoclax to treatment with ibrutinib improved outcomes in patients with relapsed or refractory MCL in a phase 3 trial.]]> Wearable Device Detects CRS in CAR-T Therapy Earlier Than Standard-of-Care Nurse Monitoring https://www.oncologynurseadvisor.com/reports/wearable-device-cytokine-release-crs-cart-therapy-myeloma-treatment/ Thu, 21 Dec 2023 16:00:00 +0000 https://www.oncologynurseadvisor.com/?p=115130 Cancer patient

Researchers investigated the feasibility of using a wearable device to monitor patients with RRMM for CRS after undergoing CAR-T therapy, compared with standard-of-care nurse-recorded monitoring. ]]> Ivosidenib vs Venetoclax: A Comparison of Efficacy, Safety of Regimens for mIDH1 AML https://www.oncologynurseadvisor.com/reports/acute-leukemia-aml-midh1-ivosidenib-venetoclax-comparison/ Wed, 20 Dec 2023 16:00:00 +0000 https://www.oncologynurseadvisor.com/?p=115094 Venetoclax and hypomethylating agents appear to be more effective when used together.

Venetoclax and hypomethylating agents appear to be more effective when used together.

This study aimed to compare treatment patterns, efficacy, and safety of 2 frontline regimens in a large cohort of patients with newly diagnosed mutant IDH1 AML.]]> SDOH Drive Disparities in Access to Cancer Care Among Undeserved Populations https://www.oncologynurseadvisor.com/reports/hematologic-sdoh-drive-disparity-cancer-care-underserved-patients/ Wed, 20 Dec 2023 15:50:00 +0000 https://www.oncologynurseadvisor.com/?p=115092 Two studies characterize hematological recovery after CAR-T cell therapy.

Two studies characterize hematological recovery after CAR-T cell therapy.

A cross-sectional survey of patients identified which social determinants of health domains contribute to delays in accessing care among patients with hematologic cancers.]]> Financial Toxicity High With Myeloma, Navigation May Help Find Aid, Solutions https://www.oncologynurseadvisor.com/reports/financial-toxicity-myeloma-navigation-may-help-find-aid-treatment-risk/ Tue, 19 Dec 2023 15:50:00 +0000 https://www.oncologynurseadvisor.com/?p=115024 The high cost of CAR-T therapy concerns patient advocates who worry about the "financial toxicity" i

The high cost of CAR-T therapy concerns patient advocates who worry about the "financial toxicity" i

A pilot project at a Philadelphia cancer center sought to improve awareness of financial assistance resources for patients with multiple myeloma.]]> Benefits of Iron Chelation Therapy Unveiled in Analysis of Low-Risk MDS https://www.oncologynurseadvisor.com/reports/myelodysplastic-syndrome-mds-iron-chelation-therapy-treatment-risk/ Mon, 18 Dec 2023 15:50:00 +0000 https://www.oncologynurseadvisor.com/?p=115001 Blood sample

An analysis of more than 2500 patients with low-risk MDS highlighted the benefits of iron chelation to reduce transfusion-related iron overload.]]> Palliative Care During In-Patient HSCT Improves Quality of Life, Reduces Depression https://www.oncologynurseadvisor.com/reports/palliative-care-hsct-stem-cell-quality-life-hematologic-malignancy-treatment/ Fri, 15 Dec 2023 16:00:00 +0000 https://www.oncologynurseadvisor.com/?p=114983 A patient with cancer receives palliative care.

A patient with cancer receives palliative care.

Researchers explored the efficacy of palliative care in the in-patient setting for patients with hematologic malignancies hospitalized for HSCT.]]> Olverembatinib Improves EFS in TKI-Resistant Chronic Phase CML https://www.oncologynurseadvisor.com/reports/olverembatinib-cml-tki-resistant-chronic-phase-efs/ Fri, 15 Dec 2023 15:40:00 +0000 https://www.oncologynurseadvisor.com/?p=114906 Female doctor talking to senior patient.

Female doctor talking to senior patient.

Olverembatinib improved event-free survival over best available therapy in patients with TKI-resistant chronic phase CML in a phase 2 trial.]]> B-Cell Depletion With Obinutuzumab May Prevent GVHD https://www.oncologynurseadvisor.com/reports/obinutuzumab-prevent-gvhd-graft-host-disease-bcell-depletion-treatment/ Thu, 14 Dec 2023 15:30:00 +0000 https://www.oncologynurseadvisor.com/?p=114946 A clinician prepares for hematopoietic stem cell transplantation.

A clinician prepares for hematopoietic stem cell transplantation.

Researchers sought to determine whether obinutuzumab administered after HSCT would lead to lower rates of GVHD.]]> Neurocognitive Outcomes Dip at 1 Month Post-CAR-T Therapy but Rebound by Month 3 https://www.oncologynurseadvisor.com/reports/neuro-cognitive-function-cart-therapy-outcomes-decline-treatment/ Wed, 13 Dec 2023 14:00:00 +0000 https://www.oncologynurseadvisor.com/?p=114917 Patient and doctor

An investigation of patients undergoing CAR-T therapy found neurocognitive outcomes decline in the first month after therapy, then patients are likely to recoup neurocognitive function by 3 months.]]>